Cargando…

Preanalytical Confounding Factors in the Analysis of Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: The Issue of Diurnal Variation

Given the growing use of cerebrospinal fluid (CSF) beta-amyloid (Aβ) and tau as biomarkers for early diagnosis of Alzheimer’s disease (AD), it is essential that the diagnostic procedures are standardized and the results comparable across different laboratories. Preanalytical factors are reported to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cicognola, Claudia, Chiasserini, Davide, Parnetti, Lucilla
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2015
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4483516/ https://www.ncbi.nlm.nih.gov/pubmed/26175714 http://dx.doi.org/10.3389/fneur.2015.00143

Ejemplares similares

No diurnal variation of classical and candidate biomarkers of Alzheimer’s disease in CSF
por: Cicognola, Claudia, et al.
Publicado: (2016)

Cerebrospinal fluid in Alzheimer's: A precious tool
por: Parnetti, Lucilla, et al.
Publicado: (2016)

Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer’s Disease and Other Neurological Disorders
por: Bellomo, Giovanni, et al.
Publicado: (2021)

Evidence for Elevated Cerebrospinal Fluid ERK1/2 Levels in Alzheimer Dementia
por: Spitzer, Philipp, et al.
Publicado: (2011)

White Matter Hyperintensities Are No Major Confounder for Alzheimer’s Disease Cerebrospinal Fluid Biomarkers
por: van Waalwijk van Doorn, Linda J.C., et al.
Publicado: (2021)

Cerebrospinal fluid biomarkers for the diagnosis and prognosis of Parkinson’s disease: protocol for a systematic review and individual participant data meta-analysis
por: Eusebi, Paolo, et al.
Publicado: (2017)

Factors Influencing the Measurement of Lysosomal Enzymes Activity in Human Cerebrospinal Fluid
por: Persichetti, Emanuele, et al.
Publicado: (2014)

Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer’s disease
por: Cicognola, Claudia, et al.
Publicado: (2018)

Measurement of CSF core Alzheimer disease biomarkers for routine clinical diagnosis: do fresh vs frozen samples differ?
por: Bellomo, Giovanni, et al.
Publicado: (2020)

Alzheimer’s Disease: Biomarkers in the Genome, Blood, and Cerebrospinal Fluid
por: Huynh, Rose Ann, et al.
Publicado: (2017)

Cerebrospinal Fluid Biomarkers and Prediction of Conversion in Patients with Mild Cognitive Impairment: 4-Year Follow-Up in a Routine Clinical Setting
por: Lanari, Alessia, et al.
Publicado: (2009)

A Consensus in Korea Regarding a Protocol to Reduce Preanalytical Sources of Variability in the Measurement of the Cerebrospinal Fluid Biomarkers of Alzheimer's Disease
por: Park, Sun Ah, et al.
Publicado: (2015)

Cerebrospinal fluid microRNAs as potential biomarkers in Alzheimer’s disease
por: Noor Eddin, Ahmed, et al.
Publicado: (2023)

Cognitive impairment in multiple sclerosis: lessons from cerebrospinal fluid biomarkers
por: Gaetani, Lorenzo, et al.
Publicado: (2020)

Assessing the Preanalytical Variability of Plasma and Cerebrospinal Fluid Processing and Its Effects on Inflammation-Related Protein Biomarkers
por: Huang, Jesse, et al.
Publicado: (2021)

Comparison of Cerebrospinal Fluid Amyloidogenic Nanoplaques With Core Biomarkers of Alzheimer’s Disease
por: Aksnes, Mari, et al.
Publicado: (2021)

Cerebrospinal Fluid Lysosomal Enzymes and Alpha-Synuclein in Parkinson's Disease
por: Parnetti, Lucilla, et al.
Publicado: (2014)

Specific Cerebrospinal Fluid SerpinA1 Isoform Pattern in Alzheimer’s Disease
por: Barba, Lorenzo, et al.
Publicado: (2022)

Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease
por: Irwin, David J., et al.
Publicado: (2013)

Diurnal Variation in P-glycoprotein-Mediated Transport and Cerebrospinal Fluid Turnover in the Brain
por: Kervezee, Laura, et al.
Publicado: (2014)

Preanalytical stability of plasma biomarkers for Alzheimer's disease pathology
por: Sunde, Anita L., et al.
Publicado: (2023)

Pro-Apoptotic Kinase Levels in Cerebrospinal Fluid as Potential Future Biomarkers in Alzheimer’s Disease
por: Paquet, Claire, et al.
Publicado: (2015)

A Strategy for Discovery and Verification of Candidate Biomarkers in Cerebrospinal Fluid of Preclinical Alzheimer’s Disease
por: Zhong, Xiaofang, et al.
Publicado: (2019)

The Associations of Cerebrospinal Fluid ApoE and Biomarkers of Alzheimer’s Disease: Exploring Interactions With Sex
por: Liu, Ying, et al.
Publicado: (2021)

Phosphatidylethanolamine Binding Protein 1 (PEBP1) in Alzheimer’s Disease: ELISA Development and Clinical Validation
por: Wojdała, Anna Lidia, et al.
Publicado: (2022)

Diagnostic biomarkers in tear fluid: from sampling to preanalytical processing
por: Bachhuber, Franziska, et al.
Publicado: (2021)

Preanalytical sample handling recommendations for Alzheimer's disease plasma biomarkers
por: Rózga, Małgorzata, et al.
Publicado: (2019)

Cerebrospinal Fluid Biomarker Candidates for Parkinsonian Disorders
por: Constantinescu, Radu, et al.
Publicado: (2013)

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
por: Cicognola, Claudia, et al.
Publicado: (2021)

Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Show Different but Partially Overlapping Profile Compared to Vascular Dementia
por: Llorens, Franc, et al.
Publicado: (2017)

Preanalytical Considerations for Joint Fluid Evaluation
por: Martinez, Caitlyn R., et al.
Publicado: (2017)

Validation and assessment of preanalytical factors of a fluorometric in vitro assay for glucocerebrosidase activity in human cerebrospinal fluid
por: Oftedal, Linn, et al.
Publicado: (2020)

Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid
por: Bjerke, Maria, et al.
Publicado: (2010)

Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementia
por: Chiasserini, Davide, et al.
Publicado: (2017)

Accumulation of Cerebrospinal Fluid Glycerophospholipids and Sphingolipids in Cognitively Healthy Participants With Alzheimer’s Biomarkers Precedes Lipolysis in the Dementia Stage
por: Fonteh, Alfred N., et al.
Publicado: (2020)

Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease
por: Parnetti, Lucilla, et al.
Publicado: (2014)

Cerebrospinal Fluid Aβ(42/40) Corresponds Better than Aβ(42) to Amyloid PET in Alzheimer’s Disease
por: Lewczuk, Piotr, et al.
Publicado: (2016)

Soluble Megalin is Reduced in Cerebrospinal Fluid Samples of Alzheimer’s Disease Patients
por: Spuch, Carlos, et al.
Publicado: (2015)

Reduction of Glycolysis Intermediate Concentrations in the Cerebrospinal Fluid of Alzheimer’s Disease Patients
por: Bergau, Nick, et al.
Publicado: (2019)

Cerebrospinal Fluid Levels of Amyloid Beta 1-43 Mirror 1-42 in Relation to Imaging Biomarkers of Alzheimer’s Disease
por: Almdahl, Ina S., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_4ju6i3a4muhdkomct7j7npc4ib